Why Odyssey Therapeutics, Inc.’s (ODTX) Stock Is Down 6.70%
As of Thursday, September 24, Odyssey Therapeutics, Inc.’s ODTX share price has dipped by 6.70%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Odyssey Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. The company pipeline includes OD-001, an oral small molecule inhibitor of receptor-interacting protein kinase 2, which is in phase 2a trial for the treatment of ulcerative colitis; OD-002, an oral small molecule SLC15A4 inhibitor designed to block TLR7/8/9-mediated pathogenic inflammatory responses activation of interferon regulatory factor 5 (IRF5); OD-003, a protein therapeutic designed to agonize tumor necrosis factor receptor 2 selectively on Treg; a TSLP/IL-33 bispecific antagonist; an oral small molecule interleukin-1 receptor–associated kinase 4 scaffolding inhibitor; and a small molecule inhibitor of IRF5. The company was incorporated in 2021 and is headquartered in Boston, Massachusetts.
Commentary & Analysis
Why Odyssey Therapeutics, Inc.’s (ODTX) Stock Is Down 5.66%
As of Wednesday, September 23, Odyssey Therapeutics, Inc.’s ODTX share price has dipped by 5.66%, which has investors questioning if this is right time to buy.Michael Rose
Why Odyssey Therapeutics, Inc.’s (ODTX) Stock Is Up 6.09%
As of Friday, September 18, Odyssey Therapeutics, Inc.’s ODTX share price has surged by 6.09%, which has investors questioning if this is right time to sell.Michael Rose
Why Odyssey Therapeutics, Inc.’s (ODTX) Stock Is Up 10.16%
As of Thursday, September 17, Odyssey Therapeutics, Inc.’s ODTX share price has surged by 10.16%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why Odyssey Therapeutics, Inc.’s (ODTX) Stock Is Up 5.50%
As of Wednesday, September 16, Odyssey Therapeutics, Inc.’s ODTX share price has surged by 5.50%, which has investors questioning if this is right time to sell.Michael Rose
Financial Summary
| Share Statistics | ODTX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $994.8 | $259.1 | 45% |
|
| Shares Out (Mil) | 30.3 | 54.3 | 37% |
|
| Institutional Ownership | 94.2% | 92.8% | 64% |
|
| Float (Mil) | 23.7 | 42.0 | 31% |
|
| Beta | na | 0.95 | na |
|
| Avg Daily Volume (000s) | 566 | 637 | 58% |
|
| Price Change (52-week) |
na | 52.5% | na |
|
| Growth | ODTX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.2% | na |
|
| Net Income (5yr) | na | (10.1%) | na |
|
| EPS (5yr) | na | 15.8% | na |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | na | (15.6%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 3 | 3 | 3 | |
| Current EPS | ($0.930) | ($4.255) | ($4.360) | |
| Month Ago EPS | ($0.930) | ($4.255) | ($4.360) | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | ($0.890) | ($4.218) | ($3.876) | |
| Year/Year Chg | (46.6%) | (91.5%) | (90.6%) | |
| Financials | ODTX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($160) | ($43) | 8% |
|
| EPS (TTM) | ($14.051) | ($1.600) | 4% |
|
| Operating Cash Flow (TTM) (Mil) | ($132) | ($32) | 5% |
|
| Net Cash Flow (TTM) (Mil) | $145 | $2 | 80% |
|
| Long-Term Debt (Q1) (Mil) | $19 | $4 | 32% |
|
| Enterprise Value (Q1) (Mil) | $654 | $175 | 36% |
|
| Valuation | ODTX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 2.36 | 2.54 | 58% |
|
| P/E | na | 18.4 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | ODTX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 68.9% | na |
|
| Net Margin | na | (72.5%) | na |
|
| ROA | (41.5%) | (47.5%) | 13% |
|
| ROE | (201.9%) | (54.9%) | 4% |
|
| Liabilities to Assets | 12.9% | 29.4% | 8% |
|
| F-Score | 2 | 3 | na |
|
Odyssey Therapeutics, Inc. did not pass any screens on 9/23/2026.
